basal cell carcinoma

Biofrontera AG ADR (NASDAQ: BFRA) is trading 53 percent above its Feb. 14 initial public offering price, justifying the company's pursuit of a U.S. market debut. The German company added a Nasdaq listing alongside a presence on the Frankfurt Stock Exchange to increase not only capital, but also...